Navigation Links
Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement

WALTHAM, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Lionbridge (Nasdaq: LIOX) today announced that it has signed a new, three-year master services agreement with a multi-billion dollar biotech company with products and services that serve patients in approximately 100 countries. With the agreement Lionbridge will become the sole provider for translation of the company's online content, which includes regulatory, marketing, training, human resources, legal, and corporate communications information. Lionbridge expects this new program to generate approximately $6 million over the term of the contract.

Lionbridge is providing the biotech company an integrated worldwide program for translation and linguistic validation across more than 40 languages. To facilitate an efficient translation process that adheres to strict regulatory compliance requirements, the client's users will access Lionbridge's Freeway® portal technology to streamline project submission, project tracking, collaboration, in-country reviews and reporting. The program will also rely on Logoport®, Lionbridge's Web-architected translation memory technology to facilitate real-time collaboration among all project participants and to assure quality. Because Freeway and Logoport are Web-based, the biotech company can take advantage of the benefits of technology without having to buy, deploy or maintain translation software.

"This new contract is indicative of strengthening demand for Lionbridge services and reflects the value we bring to multinational corporations that need to harmonize processes and manage complex requirements while serving customers worldwide," said Rory Cowan, CEO, Lionbridge. "By integrating our market leading products and services across the enterprise, Lionbridge offers a complete managed service model for multilingual content. As a result, the company gains a flexible and reliable solution for managing global content while increasing quality and consistency."

Separately, the Company announced that it now expects fourth quarter revenue to be at the high-end or above its previously provided revenue guidance range of $98-102 million as a result of new program wins and better than expected revenue volume from certain key customers. The Company will release its fourth quarter and FY 2009 results in early February 2010.

About Lionbridge Life Sciences

Lionbridge Life Sciences specializes in language services for medical device developers, pharmaceutical companies, and CROs, delivering high-quality translation, linguistic validation, and interpretation services in over 150 languages. Life Sciences clients benefit from Lionbridge's highly specialized network of medically trained linguists and professionals operating from solution centers across the world.

About Lionbridge

Lionbridge Technologies, Inc. (Nasdaq: LIOX) is a provider of translation, development and testing solutions. Lionbridge combines global resources with proven program management methodologies to serve as an outsource partner throughout a client's product and content lifecycle - from development to translation, testing and maintenance. Global organizations rely on Lionbridge services to increase international market share, speed adoption of global products and content, and enhance their return on enterprise applications and IT system investments. Based in Waltham, Mass., Lionbridge maintains solution centers in 26 countries and provides services under the Lionbridge and VeriTest brands. To learn more, visit

Lionbridge, Freeway, and Logoport are trademarks or registered trademarks of Lionbridge Technologies, Inc. in the U.S. and throughout the world. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including those statements relating to expected revenue and revenue growth during the fourth quarter. Lionbridge's actual experience may differ materially from those discussed in the forward-looking statements. Factors that might cause such a difference include the termination of customer contracts prior to the end of their term; Lionbridge's dependence on clients' product releases to generate revenues; the loss of a major client or customer; the size, timing and recognition of revenue from major clients; customer delays or postponements of services; political, economic and business fluctuations in international markets; as well as risks of additional downturns in conditions generally, and in the information technology and software industries specifically, and risks associated with competition and competitive pricing pressures; and Lionbridge's ability to forecast revenue and operating results. For a more detailed description of the risk factors associated with Lionbridge, please refer to Lionbridge's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2009 and subsequent filings.

    Sara Buda
    (781) 434-6190

SOURCE Lionbridge Technologies, Inc.

SOURCE Lionbridge Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. K-States Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year
2. The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict
3. MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie
4. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
5. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
6. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
7. BSP Raises $2.6 Million Dollars From Private Investors
8. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
9. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
10. Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Companys First Annual 2010 Micro Cap Conference
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
Breaking Biology News(10 mins):